CelLBxHealth plc ANPCF
0.01 USD 0.00 (+0.00%)
At closeNov 10, 2026, 4:00 PM EST
0.0098 Day range 0.0098
0.0098 52-week range 0.025
- YTD
- -41.67%
- 1 year
- -60.80%
News
proactiveinvestors.com CelLBxHealth looking up as it bolsters commercial pipeline CelLBxHealth PLC (AIM:CLBX, FRA:DWV) told investors it is targeting revenues of £3 million to £4 million in 2027, potentially more than doubling its expected 2026 turnover, as new pharmaceutical…
proactiveinvestors.com CelLBxHealth lands contract with Swiss biotech for clinical study CelLBxHealth PLC (AIM:CLBX, FRA:DWV) has secured an agreement with a Swiss biotechnology company to support a radiopharmaceutical clinical study, extending the use of its circulating tumour cell…
proactiveinvestors.com Cellbxhealth signs new statement of work with US pharma company CelLBxHealth PLC (AIM:CLBX, FRA:DWV), which develops technology to collect tumour cells from blood, has signed a new statement of work worth around $65,000 with an existing US pharmaceutical…
proactiveinvestors.co.uk CelLBxHealth's blood test spots hard-to-detect cells from brain tumours An independent study has found that tumour cells circulating in the blood of patients with the most aggressive form of brain cancer can be captured and analysed using technology made by CelLBxHealth…
proactiveinvestors.co.uk CelLBxHealth study detects drug targets on cancer cells rivals would miss CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the liquid biopsy company, said an independent study had shown its Parsortix system can detect the biological targets used by a fast-growing class of cancer…
proactiveinvestors.co.uk CelLBxHealth moves from cutting to converting The interim figures mark the point where CelLBxHealth PLC (AIM:CLBX, FRA:DWV) stops being a restructuring story and starts being a commercial one, says a note from Cavendish. The heavy lifting is…
proactiveinvestors.co.uk CelLBxHealth builds £3.5m weighted pipeline as revenue growth target held CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the AIM-listed cancer diagnostics company, said its commercially weighted pipeline had built to £3.5 million, supported by rising engagement from pharmaceutical…
proactiveinvestors.co.uk CelLBxHealth reaffirms revenue guidance CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the cancer diagnostics company, has told shareholders it remains on track to deliver revenues of at least £2.1 million for 2026 as it searches for a new chief…
proactiveinvestors.co.uk Cavendish backs CelLBxHealth turnaround with buy rating, 4p target Cavendish remains bullish on CelLBxHealth PLC (AIM:CLBX, FRA:DWV) with a 'buy' rating and 4p price target in the wake of its prelims earlier. The AIM-listed biotech has completed a strategic reset…
proactiveinvestors.co.uk CelLBxHealth guides for 50% revenue growth as partnership pipeline swells CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the circulating tumour cell diagnostics company, expects revenues of at least £2.1 million in 2026, representing growth of at least 50% from last year's £1.4…
proactiveinvestors.co.uk CelLBxHealth strikes US clinical collaboration with AdventHealth cancer studies CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the AIM-listed circulating tumour cell (CTC) diagnostics company, has secured a collaboration with AdventHealth, one of the largest faith-based health systems in…
proactiveinvestors.com Enbridge reports record 2025 earnings, reaffirms 2026 guidance Enbridge Inc (TSX:ENB) on Friday reported record financial results for 2025, driven by higher earnings across its operations, and reaffirmed its 2026...
proactiveinvestors.co.uk CelLBxHealth shares rise 3% as company continues to focus on cost base Shares in CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) rose 3% to 1.08p on Thursday after the company announced it would discontinue its United States Food and Drug Administration establishment…
proactiveinvestors.co.uk CelLBxHealth drops FDA device listing to cut costs and refocus on revenue growth CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) has decided to discontinue maintenance of its United States Food and Drug Administration establishment licence and device listing for the Parsortix…
proactiveinvestors.com CelLBxHealth drops FDA device listing to cut costs and refocus on revenue growth CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) has decided to discontinue maintenance of its United States Food and Drug Administration establishment...
proactiveinvestors.com Nasdaq, Dow Jones little changed as TSMC settles tech jitters 1:15pm: Market movers Shares of ImmunityBio (NASDAQ:IBRX) traded more than 30% higher after the company reported updated clinical data showing durable...
proactiveinvestors.co.uk CelLBxHealth backed for rebound by broker CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) is a recovery story with asymmetric upside. In a note published on Friday, Cavendish reiterated its 4.0p price target, implying more than 300% upside…
proactiveinvestors.co.uk CelLBxHealth enters 2026 with strong pipeline CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) said it is entering 2026 with a sharpened strategy and a focus on turning a £12.6 million sales pipeline into revenues, adding that its balance sheet…
proactiveinvestors.com CelLBxHealth enters 2026 with strong pipeline CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) said it is entering 2026 with a sharpened strategy and a focus on turning a £12.6 million sales pipeline...
proactiveinvestors.com Gold prices will keep rising on macroeconomics and geopolitical risk - UBS UBS expects gold to keep rising after hitting fresh record highs. The broker said bullion has already climbed around 7% this year after a near 65% gain in...